Chardan Capital started coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a report released on Friday morning, MarketBeat Ratings reports. The firm issued a neutral rating on the biopharmaceutical company’s stock.
Several other brokerages have also recently weighed in on DRNA. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, February 2nd. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, January 25th. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, February 1st. SunTrust Banks initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Monday, February 5th. They issued a buy rating and a $13.00 price objective for the company. Finally, Stifel Nicolaus lifted their price objective on shares of Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the stock a buy rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $11.21.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at $13.87 on Friday. Dicerna Pharmaceuticals has a 12 month low of $2.52 and a 12 month high of $15.00. The firm has a market cap of $716.27, a PE ratio of -4.04 and a beta of 2.18.
In other news, Director Bain Capital Life Sciences Inv bought 285,000 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was bought at an average cost of $7.00 per share, for a total transaction of $1,995,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 29.41% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of DRNA. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 2,094 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after buying an additional 14,517 shares in the last quarter. First Manhattan Co. acquired a new position in shares of Dicerna Pharmaceuticals in the 4th quarter valued at approximately $3,865,000. Emerald Advisers Inc. PA acquired a new position in shares of Dicerna Pharmaceuticals in the 4th quarter valued at approximately $266,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Dicerna Pharmaceuticals in the 4th quarter valued at approximately $1,878,000. Institutional investors own 75.49% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.